GLP-1 Eligibility Checker
Check if you may qualify for GLP-1 weight loss medications like Ozempic, Wegovy, Mounjaro, or Zepbound based on FDA clinical guidelines. 100% private — all calculations run in your browser.
How GLP-1 Eligibility Checker Works
Check if you may qualify for Ozempic, Wegovy, Mounjaro, or Zepbound BMI and health screening — instant results. Provide your input in the form above and the tool analyzes it instantly in your browser, giving you actionable results without sending data to any server.
Who Qualifies for GLP-1 Weight Loss Medication?
GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have transformed weight management treatment. The FDA has approved these medications for specific patient populations based on clinical trial data. For weight management, adults with a BMI of 30 or above (obesity) generally qualify. Adults with a BMI of 27 or above (overweight) may also qualify if they have at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. Previous unsuccessful attempts at weight loss through diet and exercise support your candidacy when speaking with a doctor.
FDA Eligibility Criteria Explained
The FDA uses Body Mass Index (BMI) as the primary screening metric for GLP-1 weight loss medications. For Wegovy and Zepbound, which are specifically approved for chronic weight management, the threshold is BMI 30+ without comorbidities or BMI 27+ with at least one qualifying comorbidity. For Ozempic and Mounjaro, which are primarily approved for type 2 diabetes management, the key criterion is a diagnosis of type 2 diabetes — BMI is secondary. These medications work by mimicking the GLP-1 hormone, which regulates appetite and blood sugar levels, leading to significant weight reduction in clinical trials.
GLP-1 Medications Available in 2026
Several GLP-1 medications are currently FDA-approved. Wegovy (semaglutide 2.4mg injection) and Zepbound (tirzepatide injection) are approved for chronic weight management. Ozempic (semaglutide injection) and Mounjaro (tirzepatide injection) are approved for type 2 diabetes but are also prescribed off-label for weight loss. The oral semaglutide 50mg tablet (Wegovy Pill) offers a needle-free option for weight management. Average weight loss ranges from 15-25% of body weight over 12-18 months, though individual results vary based on adherence, diet, and exercise habits.
Contraindications and Safety Considerations
GLP-1 medications are not appropriate for everyone. They are contraindicated during pregnancy and breastfeeding due to potential risks to the fetus. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use these medications. GLP-1 drugs are not currently approved for weight management in individuals under 18. Common side effects include nausea, vomiting, and diarrhea, which typically improve over time. Always discuss your complete medical history with your healthcare provider before starting any GLP-1 medication.
Next Steps After Checking Eligibility
If this screening suggests you may be eligible, the next step is scheduling an appointment with your healthcare provider. Bring your BMI results, list of current medications, and medical history. Your doctor may order blood work including HbA1c, lipid panel, and thyroid function tests. Insurance coverage varies — many plans now cover FDA-approved GLP-1 medications for qualifying patients. Manufacturer savings programs and telehealth providers may offer additional access options. If you do not currently meet the criteria, focus on sustainable lifestyle changes including balanced nutrition and regular physical activity, and discuss alternative options with your doctor.
Frequently Asked Questions
Who qualifies for GLP-1 weight loss medication?
Adults with a BMI of 30 or above (obesity) generally qualify for FDA-approved GLP-1 weight management medications like Wegovy and Zepbound. Adults with a BMI of 27 or above (overweight) may also qualify if they have at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea.
What BMI do I need for Wegovy or Zepbound?
For Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide), the FDA requires a BMI of 30 or higher, OR a BMI of 27 or higher with at least one weight-related comorbidity. Your doctor will confirm eligibility based on your full medical evaluation.
Can I get Ozempic if I don't have diabetes?
Ozempic (semaglutide) is FDA-approved specifically for type 2 diabetes management. While doctors can prescribe it off-label for weight loss, it is not FDA-approved for that purpose. Wegovy, which contains the same active ingredient at a higher dose, is the FDA-approved option for weight management.
What are the contraindications for GLP-1 medications?
GLP-1 medications are contraindicated during pregnancy and breastfeeding, in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and are not approved for weight management in individuals under 18. Always disclose your full medical history to your prescribing doctor.
How much does GLP-1 medication cost without insurance?
Without insurance, GLP-1 medications can cost $800 to $1,500+ per month for brand-name versions. However, many insurance plans now cover FDA-approved options for qualifying patients. Manufacturer savings cards, telehealth programs, and compounded versions may reduce costs significantly. Ask your doctor and pharmacist about available options.
Is the Wegovy pill as effective as the injection?
The oral semaglutide 50mg tablet (Wegovy Pill) has shown clinically significant weight loss in trials, though the injection form typically shows slightly higher average weight loss. The pill offers a needle-free alternative for patients who prefer oral medication. Your doctor can help determine which form is best for you.
What should I ask my doctor about GLP-1 medications?
Ask about your specific eligibility, expected results, potential side effects (nausea, vomiting, diarrhea are common initially), how long you would need to take the medication, insurance coverage options, and what lifestyle changes should accompany the medication for best results. Also ask about monitoring and follow-up schedules.